Effect of bovine pellucid zone 3 monoclonal antibodies on B cell lymphoma 2 expressions of granulosa cell and mice (Mus musculus) follicle diameter

Objective:To evaluate the effects of pellucid zone 3 monoclonal antibodies against B-cell lymphoma 2 (BCL-2) expression and mice follicle diameter at various time periods.Methods:The animal model of this study was 36 Balb/c mice (Mus musculus). A true experimental design was used with a post-test only control group approach. BCL-2 expression was observed using immunohistochemistry, while the follicle diameter was observed by haematoxylin-eosin staining. The data was analyzed using nested ANOVA to compare the results of the mean expression of BCL-2 on the 5th and 20th day of observation in the pre-antral and antral follicle between the control and treatment groups.Results:No significant differences were found in BCL-2 gene expression. There were also no significant differences in BCL-2 expression on the 10th day of pre-antral follicle analysis. Moreover, there were no significant differences between the mean follicle diameter on the 5th, 10th, and 20th day of pre-antral and antral follicle development between the control and treatment groups. The addition of bovine pellucid zone 3 (bZP3) monoclonal antibodies on the 5th and 20th day of observation did not decrease the expression of BCL-2 gene in the pre-antral and antral follicle of mice. Administering bZP3 monoclonal antibodies on the 10th day of observation did not affect BCL-2 expression in the pre-antral follicle but did decrease BCL-2 expression in the antral follicle. Supplying bZP3 monoclonal antibodies on the 5th, 10th and 20th day did not affect the diameter of pre-antral and antral follicles of the mice.Conclusion: The monoclonal antibodies bovine zona pelusida 3 has the potential to be developed as a safe immunocontraception preparation.

Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer

Metastatic colorectal cancer (mCRC) continues to be counted as a major health problem. The introduction of newer cytotoxics, irinotecan and oxaliplatin, has achieved a significant improvement in survival rates. Novel targeted therapies (bevacizumab, and cetux-imab) in combination with most efficient chemotherapy regimens have pushed the median survival beyond the 2-year mark and increased the proportion of patients which could benefit from resection of metastatic lesions. In addition, several studies have proved that the CRC mutation profiles should influence patient selection or stratif ication in prospective trials. KRAS mutational status represents a paradigm for biomarker development in the era of molecular targeted therapies. The present article is an overview of the most important studies in the development of biomarkers for the optimization of anti-epidermal growth factor receptor (anti-EGFR) treatment in mCRC, beyond KRAS mutations, which is a work in progress. The aim will be to identify molecular markers that might be used to select patients with a higher probability of response to anti-EGFR monoclonal antibodies. Overall the accumulating evidence of the molecular biology of CRC has substantially changed the approach to mCRC treatment and has given clinicians more rational options for treating this illness.

猪圆环病毒3型Cap蛋白单克隆抗体的制备及阻断ELISA检测方法的建立

旨在建立检测猪圆环病毒3型(PCV3)抗体的阻断ELISA方法,本研究利用原核表达的PCV3Cap重组蛋白免疫BALB/c小鼠制备获得了一株分泌阻断效果良好抗体的杂交瘤细胞株2E6。以重组Cap蛋白作为包被抗原,以辣根过氧化物酶(HRP)标记的2E6单克隆抗体作为检测抗体,经条件优化后建立了一种检测PCV3抗体的阻断ELISA方法。用建立的阻断ELISA方法检测50份临床阴性血清,计算阻断率(PI)的临界值,以此来确定该方法的判定标准:当PI≤28.30%时,判定结果为阴性;当PI≥35.05%时,判定结果为阳性;当28.30%<PI<35.05%时,判定为可疑,重复一次试验后如果结果仍为可疑,则判定为阳性。特异性试验表明该方法与猪圆环病毒2型(PCV2)、猪伪狂犬病病毒(PRV)、猪繁殖与呼吸综合征病毒(PRRSV)以及猪瘟病毒(CSFV)的阳性血清均无交叉反应;敏感性试验表明其检测效价可达到1:128;重复性试验表明批内与批间的变异系数均小于10%;符合性检验表明该方法与PCV检测金标准免疫过氧化物酶单层试验(IPMA)比对的Kappa值达0.9,具有高度的一致性。综上所述,本研究建立的阻断ELISA方法具有良好的特异性与较高的符合率,可用于后期进行PCV3抗体的检测,为PCV3的流行病学调查与临床诊断提供技术支持。

Induction of specific immunosuppression of cardiac allograft rejection withmonoclonal antibodies to CD44, LFA-1 and ICAM-1

Objective:To evaluate the immunosuppressive effect of monoclonal antibodies (McAb) against cell surface adhesion molecules on transplant rejection. Methods: C57BL/6 (H-2b) mouse cardiac grafts were transplanted into BALB/c(H- 2d) mice. This model was used to investigate the possibility of immunosuppressive induction with CD44 McAb, leukocyte function associated antigen (LFA-1) and intercellular adhesion molecule (ICAM-1). Results: Treatment of the allograft recipients with CD44 McAb alone, or both LFA-1 and ICAM-1 or combination of these 3 McAb significantly prolonged the cardiac allografts survival as compared with PBS controls (P<0.01). The combination of anti-CD44 and ICAM-1 and LFA-1 McAb was shown to produce more significant prolongation of grafts survival than anti-CD44 McAb alone or both anti-ICAM- 1 and LFA-1 McAb (P < 0.01). Histological examination of the grafts treated with the McAb displayed greatly reduced mononuclear cell infiltration. The proliferation of spleen cells from recipient BALB/c with McAb treatment was significantly inhibited in response to the stimulators of C57BL/6 spleen cells, but increased upon the stimulation of C3H/He (H-2k) spleen cells, as demonstrated by mixed lymphocyte reaction. Similarly, the cytotoxic activity against donor H-2-compatible (H-2b) target cells, EL-4 cells, was significantly suppressed. The spleen cells from allografted recipient BALB/c mice with McAb treatment induced specific tolerance for C57BL/6 cardiac grafts in allografted recipients, whereas those from allografted BALB/c mice without McAb treatment induced acute rejection. Conclusion: These results indicate that antiadhesion therapy using a combination of McAb to adhesion molecules can induce specific immunosuppression of transplant rejection.

Inhibitory Effect of Anti-HER-2 Anti-CD3 Bi-specific Antibody on the Growth of Gastric Carcinoma

To evaluate the effect of anti-HER-2 × anti-CD3 bi-specific antibody（BsAb） on the growth of HER-2/neu-expressing human gastric carcinoma in vitro and in vivo, an MTT assay was carried out to test the inhibitive rates of herceptin, anti-CD3 and BsAb antibodies on SGC-7901 gastric carcinoma cells. Immunocytochemistry methods were used to test the HER-2 level of SGC-7901. Nude mice models were employed to test the effect of HER-2 CD3 BsAh combined with effector ceils（ peripheral blood lymphatic cells of healthy human beings） on the growth of tumors in animals. Compared with that of the untreated control group, the tumor cell growth rates in vitro and in vivo will both be significantly inhibited when treated with effector cells combined with anti-CD3 McAb, herceptin or HER2 CD3 BsAb （p 〈0. 05）, and the growth inhibition is the most remarkable in the group treated with HER2 CD3 BsAb combined with effector cells. The growth of tumor xenografts will also be significantly inhibited in the group treated with HER2 CD3 BsAb combined with effector cells when compared with that in the group treated with anti-CD3 McAb or the group treated with herceptin combined with effector cells（p 〈0. 05）. We can conclude that HER-2/neu is possibly a useful target for immunotherapy of gastric carcinoma, and anti-HER2 × anti-CD3 BsAb has evident anti-tumor efficacy both, in vitro and in vivo.

鸭腺病毒3型Fiber-2蛋白单克隆抗体的制备及初步应用

为进一步研究鸭腺病毒3型(DAdV-3)Fiber-2蛋白,研究通过PCR扩增fiber-2基因,构建p ET32a-DAdV3-fiber2原核质粒,表达并纯化蛋白,以纯化的蛋白为免疫原,免疫6周龄雌性BALB/c小鼠制备抗Fiber-2单克隆抗体杂交瘤细胞,采用间接免疫荧光试验和免疫印迹试验进行鉴定,并用于DAdV-3 Fiber-2杆状病毒表达产物的鉴定。结果显示:原核表达获得1.77 mg/mL Fiber-2蛋白,筛选获得2株阳性单克隆细胞株2E10E4和4F7F10,两株单克隆抗体均为IgG 1型,轻链类型为κ;DAdV-3感染的LMH细胞中存在特异性荧光,免疫印迹试验确认在约59 ku处出现特异性条带;采用制备的单克隆抗体确认了表达Fiber-2蛋白的重组杆状病毒。研究获得了针对DAdV-3 Fiber-2蛋白的单克隆抗体,为深入探究Fiber-2在DAdV-3感染机制中的作用以及为建立DAdV-3抗原免疫测定技术奠定了基础。

Expression of Anti-CD4 Human/Murine Chimeric Antibody and Their Killer Tumor Activity

From the mouse hybridoma cell line secreting an anti-CD4 monoclonal antibody (McAb), total RNA was prepared. The VH and VL genes were amplified by RT-PCR with family specific primer pairs. The PCR products were cloned into pGEM-T vectors, then tranfected into JM109. The VH and VL genes were snalyzed by automatic DNA sequencer. According to Kabat classification, the VH and VL genes belong to the mouse ig heavy subgroup Ⅱ(A) and x chain subgroupⅢ, respectively. The VH and VL genes were subcloned into pr1-Expr and Pk Expr respectively, then transfected into XL2-Blue. The VH- Pr1 and VL- pk were trans feeted by electroporation into mouse myeloma cell X63Ag8. 653. The transfectoma cells were selected by G418 screening, and then supernatant of cultured transfectoma were analyzed by ELISA and immunofluorescence techniques.We have acquired transfectoma cells secreting anti-CD4 chimeric antibodies.These chimeric antibodies are able to kill tumor cells specifically in vitro.

花生致敏蛋白Ara h 3单克隆抗体的制备及其免疫学特性鉴定

以Ara h 3为免疫原免疫小鼠。选取血清效价高的小鼠再次免疫,制备出脾细胞后与骨髓瘤细胞一起进行细胞融合,得到杂交瘤细胞株,筛选阳性株制备大量单克隆抗体。通过酶联免疫吸附试验(ELISA)对制备的单克隆抗体进行效价测定、敏感性测定和特异性测定。通过蛋白质免疫印迹试验进一步验证其特异性。结果表明:免疫性较好的4B2单克隆抗体经纯化后的效价为1∶5.12×10^(5)。由敏感性测定得知4B2单克隆抗体的半抑制浓度(IC_(50))为389 ng/mL,证明其具有较好的敏感性,交叉反应率小于0.5%,成功制备出纯度高、效价高、敏感性好、特异性强的Ara h 3鼠源单克隆抗体,为建立免疫学快速检测方法奠定了基础。

日本血吸虫信号蛋白14-3-3的虫体免疫定位

目的 研究抗重组日本血吸虫信号蛋白 1 4 3 3(rSj1 4 3 3)单克隆抗体对天然Sjl4 3 3的结合活性 ,观察Sj1 4 3 3在虫体内的定位。 方法 从阳性钉螺体内逸出尾蚴 ,感染家兔 ,分别于感染后 1 5d和 4 2d剖杀 ,静脉灌注法收集童虫和成虫制备冰冻切片。利用rSj1 4 3 3单克隆抗体 ,间接免疫荧光法探讨信号蛋白 1 4 3 3虫体内的分布。 结果 免疫荧光染色结果显示 ,rSj1 4 3 3单克隆抗体可特异性地结合天然Sj1 4 3 3抗原表位 ,背景清晰 ,Sj1 4 3 3广泛分布在雌、雄成虫的皮层、皮下层、肌层和实质层 ,前三种组织中特异性荧光呈线状分布 ,实质中特异性荧光弥散 ;童虫中Sj1 4 3 3也广泛的分布在皮层、皮下层、肌层和实质层。 结论 免疫荧光染色成功地确定了Sj1 4 3 3蛋白在成虫和 1

日本血吸虫重组信号蛋白14-3-3的纯化及抗体制备

目的 制备日本血吸虫(中国大陆株)信号蛋白Sj14-3-3的多克隆抗体与单克隆抗体。方法 将合Sj14-3-3重组蛋白的凝胶条带冻干磨粉,免疫家兔,制备抗Sj14-3-3多克隆抗血请;用电洗脱纯化的Sj14-3-3免疫BALB/c小鼠,用杂交瘤技术制备抗Sj14-3-3单克隆抗体。测定所得抗体效价及特异性鉴定。结果 获得大量纯化的表达产物;制备的多克隆抗血清双扩效价达1:8～1:64。获得1株能稳定分泌抗Sj14-3-3单抗的杂交瘤细胞株4D9,单抗亚类为IgG1。此株单抗能与重组Sj14-3-3蛋白发生特异性反应。结论 获得了高度敏感、特异的抗Sj14-3-3多克隆抗血清及稳定分泌抗Sj14-3-3单抗的杂交瘤细胞。

日本血吸虫重组信号蛋白14-3-3(rSj14-3-3)及其单克隆抗体用于诊断的价值

目的探讨纯化的日本血吸虫重组信号蛋白14-3-3(rSj14-3-3)及其相应单克隆抗体对日本血吸虫病的诊断价值。方法利用纯化的rSj14-3-3抗原和可溶性虫卵抗原(SEA)间接ELISA方法检测急、慢性日本血吸虫病患者血清中特异性抗体;以纯化的抗rSj14-3-3单克隆抗体包板,以兔抗rSj14-3-3多抗和酶标羊抗兔多抗为检测系统的酶标夹心法检测患者血清中的循环抗原。结果用rSj14-3-3检测急、慢性血吸虫病患者血清中特异性抗体的阳性率分别为100%和933%,用抗rSj14-3-3单克隆抗体检测循环抗原的阳性率分别为100%和956%,两者联合检测的总阳性率分别为100%和978%;经治疗后2、4、6、12个月,抗体转阴率分别为387%、548%、75%、90%,血清循环抗原转阴率分别为177%、419%、55%、85%,两者联合检测的总转阴率分别为452%、63%、85%、90%;对正常人血清的检测未见假阳性反应,与华支睾吸虫病和钩虫病患者血清出现轻微的交叉反应;用SEA检测抗体的阳性率分别为978%和956%,与正常人及华支睾吸虫病和钩虫病患者血清均有不同程度的交叉反应,治疗后2、4、6、12个月阴转率分别为32%、65%、125%、15%。结论rSj14-3-3检测急慢性血吸虫病患者血清中的特异性抗体和利用抗rSj14-3-3单克隆抗体检测循环抗原具有高度的特异性和敏感性。

牛副流感病毒3型NP单抗的制备及初步应用

为制备牛副流感病毒3型(BPIV3)核衣壳蛋白(NP)单克隆抗体(MAb),本研究利用原核表达并纯化的重组NP(rNP)免疫BALB/c小鼠,取免疫后小鼠脾细胞与骨髓瘤细胞SP2/0融合。采用以BPIV3为检测抗原的间接ELISA方法筛选阳性细胞克隆,经3次克隆纯化后获得1株稳定分泌抗NP特异性MAb的杂交瘤细胞株(5E5)并制备腹水,采用rNP及BPIV3包被的ELISA效价分别是2×106和1.28×105。间接ELISA、western blot、IFA试验表明该MAb具有良好的反应性和特异性。经抗体亚类鉴定该MAb亚类为IgG1/κ。特异性试验表明该MAb不与牛传染性鼻气管炎病毒、牛病毒性腹泻病毒反应。免疫组化试验表明该MAb可以检测BPIV3感染动物体内的病原。该MAb还可用于建立检测BPIV3病原及抗体的诊断方法,同时为研究NP的结构和功能提供了条件。

重组人14-3-3zeta亚型单克隆抗体的制备、鉴定及初步应用

目的制备重组人14-3-3zeta亚型单克隆抗体(McAb),并检测14-3-3蛋白在人体组织器官的分布。方法将筛选出分泌抗人14-3-3zeta的杂交瘤细胞注射入BALB/c小鼠腹腔,制备腹水McAb,用辛酸-饱和硫酸铵沉淀法纯化,并鉴定其效价、纯度、浓度、特异性以及与天然抗原的亲和力,再用此单抗检测14-3-3蛋白在人体组织器官的分布。结果腹水及纯化后的单克隆抗体的效价分别为1∶107和1∶106。纯化后的纯度达97%,浓度为5mg/ml,能识别天然的人14-3-3蛋白,并能有效地识别兔和鼠脑组织的14-3-3蛋白。在人脑、肾、肺、肝、胃、卵巢、乳腺、结肠、胰腺等组织器官中,均检出14-3-3蛋白。结论已成功制备出重组人14-3-3zeta亚型单克隆抗体,并应用于实际检测,为研究14-3-3蛋白在机体生理和病理情况下的作用机制奠定了基础。

抗人CA15-3单克隆抗体的制备、鉴定及化学发光检测体系的建立

目的获得抗人CA15-3单克隆抗体（mAb），建立CAl5-3双抗体夹心化学发光检测体系。方法人CAl5-3糖抗原免疫小鼠后，通过细胞融合，筛选到阳性杂交瘤细胞。杂交瘤细胞扩大培养后，纯化获得抗CAl5-3的mAb。对抗体进行纯度、效价、表位和亚型的鉴定并建立双抗体夹心检测CAl5—3化学发光体系，对该体系进行准确度、最低检测限、线性、重复性与特异性评估。结果获得5株阳性信号较强的杂交瘤细胞（分别为#3-1-3、#5-2-2、#11-2-2、#12—1—3和#16-1-3）。其分泌的抗体效价均大于10qg／mL，轻链均为K链，重链#3—1-3为IgG2a、#5-2-2与#12-1-3为IgG2b、#11-2-2与#16—1-3为IgG3。双抗体夹心体系在（0。300）U／mL范围内线性关系良好，其准确度的回收率为97．45％；最低检测限为0．59U／mL；线性相关系数为0．9978；低高值的变异系数（cy）均小于10％；与肿瘤标志物AFP、CEA、CAS0、CAl9-9和CA72-4均不交叉。结论成功制备了抗人CAl5-3mAb，建立了双抗体夹心检测CAl5-3化学发光体系。

蓝舌病病毒3型VP5蛋白单克隆抗体的制备及其抗原表位鉴定

为制备血清3型蓝舌病病毒(BTV)VP5蛋白的单克隆抗体(MAb)及鉴定其抗原表位,本研究利用pMAL-C4x原核表达系统表达、纯化的重组VP5蛋白免疫BALB/c小鼠,取其脾淋巴细胞与SP2/0细胞进行融合,并以Bac-to-Bac昆虫杆状病毒表达系统表达、纯化的重组VP5蛋白为包被抗原,通过间接ELISA筛选出一株稳定分泌抗BTV3 VP5蛋白的MAb杂交瘤细胞株(3F2)。间接免疫荧光结果表明:MAb 3F2与BTV3、BTV5、BTV9、BTV16呈阳性反应;与BTV6、BTV7、BTV13、BTV21呈弱阳性反应;与其它BTV血清型均呈阴性反应。利用原核表达的麦芽糖结合蛋白(MBP)融合短肽对MAb 3F2识别的抗原表位进行鉴定,结果表明:该MAb识别的抗原表位为89PGERGIQMKIKEIEEE104。氨基酸序列比对结果显示该表位在不同地域来源的BTV3株间比较保守。该MAb的制备和鉴定为进一步研究VP5蛋白的结构和功能奠定了基础。

重组人3型腺病毒六邻体蛋白单克隆抗体的制备及鉴定

目的制备抗人3型腺病毒六邻体蛋白的单克隆抗体并对单抗进行鉴定。方法用纯化的重组六邻体蛋白免疫BALB/c小鼠,取其脾细胞与骨髓瘤细胞融合。经ELISA间接法筛选和克隆化培养,获得4株分泌抗腺病毒六邻体蛋白单克隆抗体的杂交瘤细胞,纯化其腹水获得单抗。使用ELISA、Western blot和中和实验等方法鉴定单抗的敏感性、特异性以及中和活性。结果ELISA和免疫印迹结果表明这4株单抗与腺病毒六邻体蛋白可以特异性结合。而且,4C6株单抗具有中和活性。结论获得了4个单抗为腺病毒六邻体蛋白的单克隆抗体,可用于3型腺病毒的早期诊断和药物治疗的研究。

HCV NS3蛋白单克隆抗体的制备及其识别区域的分析

目的制备针对丙型肝炎病毒(HCV)非结构区NS3全长蛋白的单克隆抗体(MAb),并分析获得的单抗识别表位所在区域,为建立以NS3蛋白为靶位的抗HCV研究提供抗体工具。方法用原核表达的HCV非结构区NS3全长蛋白作为免疫原,采用小鼠腹股沟皮下NC膜包埋法免疫小鼠,按常规杂交瘤细胞的制备方法,经细胞融合、克隆化制备抗NS3蛋白的MAb。用间接免疫荧光法和Westernblot鉴定其特异性。分别构建NS3丝氨酸蛋白酶(NS3蛋白的N末端13)编码基因的真核表达质粒pcDNA3.1()ns3p、NS3解旋酶(NS3蛋白的C末端23)编码基因的真核表达质粒pcDNA3.1()ns3h,将其瞬时转染COS7细胞后,以获得的单克隆抗体作为一抗,通过免疫荧光分析获得单抗识别表位所在的区域。结果获得了2株抗NS3蛋白的单克隆抗体,这2株MAbs均特异识别NS3蛋白,并确定了它们的结合区域。结论获得了针对NS3蛋白的单克隆抗体,并对其单抗识别表位所在的区域进行了分析,为下一步进行以NS3蛋白为靶位的抗HCV研究奠定了良好的基础。

急性期川崎病信号转导和转录激活因子3的表达及意义

目的:探讨急性期川崎病IL-6介导信号转导和转录激活因子3的表达及意义。方法:急性期川崎病(KD)患儿64例,感染发热患儿18例,正常同年龄对照42例。采用Western blot检测外周血单个核细胞(PBMCs)IL-6刺激前后总蛋白,核蛋白STAT3,pSTAT3的表达水平。荧光定量PCR检测PBMCs IL-6刺激前后及IL-6R抗体阻断后STAT3 mRNA的表达水平。结果:急性期KD患儿PBMCs用IL-6刺激前、后总蛋白STAT3,pSTAT3表达水平高于正常儿童;核蛋白则为IL-6刺激前KD患儿STAT3,pSTAT3表达与正常儿童无明显差异,IL-6刺激后KD患儿STAT3,pSTAT3表达明显高于正常儿童。IL-6刺激前、后KD患儿STAT3 mRNA水平(1.15±0.19,1.74±0.59)均高于感染发热患儿(1.07±0.21,1.45±0.32)及正常儿童(0.56±0.37,1.03±0.51);KD冠脉损伤组(1.19±0.21,1.81±0.47)STAT3 mRNA高于冠脉未损伤组(1.13±0.29,1.73±0.48)。经IL-6R抗体阻断后,KD患儿STAT3 mRNA水平低于IL-6刺激前、后KD患儿及感染发热组(0.99±0.15)。结论:急性期KD患儿体内存在刺激STAT3表达和活化的因素,体外IL-6刺激能增强STAT3的表达和活化并进入细胞核;阻断实验提示IL-6在KD患儿STAT3过度表达、活化中起主导作用,本研究为用IL-6R阻断剂治疗川崎病提供了实验证据。

磷脂酰肌醇蛋白聚糖3的原核表达及单克隆抗体制备

人磷脂酰肌醇蛋白聚糖3(GPC3)是一个肝癌潜在的诊断标志物和治疗靶点。为获得抗GPC3单克隆抗体,用PCR方法克隆GPC3基因,利用酶切位点将该序列插入pGEX-2T载体,构建了pGEX-2T-gpc3表达载体。转化大肠杆菌BL21(DE3)菌株,经IPTG诱导,获得高效表达。经纯化后获得分子量为58 kD的蛋白。以该重组蛋白为免疫原,通过免疫BALB/c小鼠,经过细胞融合和筛选获得1株抗该重组蛋白的单克隆抗体1F3。Western blot分析显示,该抗体具有较好的特性,可用于GPC3蛋白的功能和应用研究。

抗人分化抑制因子3蛋白单克隆抗体的制备和鉴定

目的分化抑制因子3(inhibitor of differentiation3,Id3)是重要的细胞生长调控分子,在细胞增殖、分化等过程中发挥重要作用。文中探讨在大肠杆菌中表达及纯化重组人Id3蛋白,制备抗人Id3单克隆抗体(McAb),以进一步研究Id3的生物学功能及其临床应用。方法将重组表达载体Id3/pET32a转化大肠杆菌BL21(DE3),用异丙基β-D硫代半乳糖苷(IPTG)诱导转化菌表达Id3重组融合蛋白(Trx-His-hId3),通过镍亲和层析柱纯化Trx-His-hId3。以纯化的Id3重组蛋白为免疫原,免疫BALB/c小鼠,采用杂交瘤技术制备Id3McAb,应用酶联免疫吸附试验(ELISA)及Western blot进行抗体鉴定。结果经免疫小鼠、脾细胞分离、细胞融合及克隆筛选等步骤,筛选出2株分泌抗人Id3McAb的杂交瘤细胞株,分别命名为McAb6G7和6G9,免疫球蛋白亚类鉴定均为IgG1亚类。Western blot分析表明,McAb6G7和6G9能与重组人Id3蛋白特异性结合。间接ELISA法检测2株细胞冻融前后所产生上清中的抗体效价均分别为1∶1000、1∶5000。结论成功制备了抗人Id3McAb,为研究该蛋白的功能提供了有利工具。